Hepatitis C, Direct-acting Antivirals and Private Insurance Denials

In 2011 the U.S. Food and Drug Administration approved two new Direct-acting Antivirals (DAA’s) for the treatment of the hepatitis C virus (HCV). Chronic hepatitis C is one of the leading causes of liver disease. The World Health Organization (WHO) estimates that between 350,000 and 500,000 people die each year due to hepatitis C related liver diseases. Despite the positive results of DAA’s, health insurance companies may deny treatment in favor of older, less expensive, and less effective options.

If you have been denied coverage for DAA treatment by your health insurance carrier, contact Law Offices of Gary Green today for a free consultation. 1-888-4423-7947 or ggreen@gGreen.com.

Print Friendly